Transaction Report:
The data is overall clear and consistent with the view that Hfq supports the OmrA/B action by binding to the ydaM mRNA through the distal face resulting in the structural rearrangement. However, I hesitate to agree with the authors' claim that this work has uncovered a different and new mechanism of Hfq action. I have two major criticisms on this work/manuscript. 1) The major role of Hfq is certainly to support the sRNA action by stimulating the sRNA-mRNA base pairing. The mechanism by which Hfq stimulates the base pairing between two RNAs is not completely uncovered yet though several models, not mutually exclusive, have been proposed. The structural rearrangement of mRNA and/or sRNA by Hfq is a well-known model among them. Therefore, the authors' model is not new and not different from the conventional model. The contribution of the present work may be to have shown clearly that the structural rearrangement of a target mRNA upon Hfq binding through the distal face is critical for Hfq action.
2) The structural rearrangement model does not exclude the possibility that Hfq also provides the platform for base-pairing between sRNAs and mRNA. The authors argue that the Hfq-sRNA interaction is not required for the OmrA/B action on ydaM mRNA because the proximal and rim mutations in Hfq do not affect the OmrA/B action in vitro and opening the ydaM mRNA by a DNA oligo compensates the Hfq action in vitro. However, it is not clear at this stage whether the HfqsRNA interaction is also required or not for the OmrA/B action on ydaM mRNA in vivo. It is important that not only the hfq distal mutation but also the hfq proximal and rim mutations fail to support the OmrA/B action on the ydaM mRNA in vivo. The authors believe that the hfq proximal and rim mutations fail to support the OmrA/B action because OmrA/B are destabilized by these mutations. However, this interpretation needs to be tested experimentally. One of the useful experiments is to test the effect of overexpression of OmrA/B in cells expressing an Hfq variant carrying the proximal and rim mutations. If the authors' model is correct, it is expected that overexpression of OmrA/B may inhibit the ydaM translation even when the proximal face and rim of Hfq are mutated.
Referee #2:
In this clearly-written and carefully-prepared manuscript, the authors describe how the RNA chaperone protein Hfq promotes OmrA/OmrB small RNA-mediated translational repression by remodeling the leader of the mRNA encoding the diguanylate cyclase YdaM/DgcM to allow small RNA base pairing. The strongest evidence for this model is that an oligonucleotide, which blocks the formation of the secondary structure preventing small RNA pairing, restores regulation in the absence of Hfq in vitro. The study nicely illustrates how the effects of Hfq, independent of its broadly-known consequences for sRNA stability, can be examined with purified components I only have two minor quibbles:
1. The authors could further test their model in vivo with select point mutations that disrupt the inhibitory secondary structure.
2. The authors should acknowledge the alternative/"official" name for ydaM is dgcM.
Referee #3:
Wagner and coworkers examine how the Lsm family RNA binding protein Hfq works as an RNA chaperone in promoting the regulation by two very similar sRNAs, OmrA and OmrB, of the mRNA target ydaM, encoding a diguanylate cyclase. The target is of interest because it plays an important role in biofilm formation, and in fact the authors identify it based on the finding that abrogation of regulation of previously identified OmrA/B targets is not sufficient to block the OmrA/B repression of biofilm formation. The focus here is on the mechanism of regulation by Hfq. Rather than serving as a platform for both sRNA and mRNA binding and annealing, the authors provide strong evidence to support a model that Hfq works as a structural remodeler of ydaM mRNA, and that this remodeling is necessary to allow OmrA/B interaction with the ydaM RNA and thus regulation. The findings described here are of significant interest, and probably provide the best evidence thus far for a significant role of Hfq in a remodeling to then recruit sRNAs to regulate. The manuscript is well written, and generally clear. Many of the comments below are for further clarification, although a bit more interpretation or consideration of both the physiological and mechanistic context would be welcome.
Specific comments: 1. Given that this paper suggests that multiple levels of biofilm formation are regulated by OmrA/B, it would be helpful to have a little more information on the contribution of each of the known targets, even if it isn't the focus of this paper. While this is not essential it would be a useful addition. a. Fig. 1B is a nice demonstration that OmrA/B do something novel for curli formation. Can the repression of curli by disrupting either target or both targets tested in Fig. 1B be quantitated (by measurement of CsgD levels, possibly), in addition to the indicator plates in Fig. 1B and Fig. S1 ? b. Does abolishing regulation of ydaM either alone or in the double mutant used in Fig. 1B now prevent OmrA/B repression of biofilm? 2. Fig. 2A : The authors note in the legend that the hfq null mutant expresses lower ydaM-GFP. Is there an explanation for this? Is it related to the slower growth of the hfq null and the GFP assay? Do they know if this is also true for endogenous YdaM, suggesting possible additional roles for Hfq in regulating this gene? 3. Fig. 4 : Text (p 9) notes protection with Hfq of regions G32-G39, not shown in Fig. 4B . Does that suggest that interaction of 5' and 3' ends of ydaM RNA shown in Fig. 4B does not occur? Any evidence this part of the ydaM leader is needed for efficient regulation? 4. Fig. 4 : The authors interpret the protection of the lower cyan box region due to structural rearrangements; can they rule out another Hfq binding site for the protection? Clarify whether the structures in Fig. 4B are based on both mFold prediction and experimental data or only the experimental data. 5. P. 9, top, Fig. 4 : Only if the flanking sequence, apparently not protected, is included are there two (AAN)3 motifs. Is it accurate to say the outside sites are not protected (they don't appear to be in Fig. 4) ? The enhanced cleavage in the middle is noted but not really discussed. Do the authors think there are interactions between the two sub-motifs that are affecting the rearrangement and binding? 6. One element of interest here are the distinctions found between how OmrA and OmrB can act to interact with Hfq and this target. The differential binding to Hfq, including the suggestion that OmrA may not require proximal binding for function (aside from effects on stability in vivo, presumably) may be worth more discussion. Why is OmrA so dependent on rim binding? Is it possible to identify or predict the region in OmrA that interacts with site 2 in ydaM? 7. Fig. 7 : The data on a critical role of the distal face of Hfq would probably support both the usual model in which Hfq acts as a platform to bring together sRNA and mRNA and the remodeling model presented here. Or is this data only compelling in combination with Fig. S6 (see next point)?
Would mutations in the ARN sites and probing in the presence of the Hfq oligo provide more direct evidence for remodeling? 8. Data in Fig. S6 provides important support for the model (ability of OmrA/ydaM/Hfq complex to form win proximal Hfq mutant; confirmation of critical role for Hfq distal face and rim face); consider moving this to the major figures. 9. Given that all of the results here are under OmrA/B overproduction conditions, is there evidence for the endogenous levels of OmrA/B in regulation of curli and the ydaM target? 10. The model here, for Hfq remodeling allowing interaction of sRNAs, was suggested initially for RyhB by Geissmann and Touati, as the authors discuss. While that case may or may not still be accurate, the authors may want to consider how widespread this mode of regulation might be. Is it likely dependent on particular types of Hfq binding sites in the target? RprA has also been found to repress ydaM (as well as csgD), and the pairing region appeared, in a quick reading (Mika et al, 2012) , to overlap the OmrA/B sites. Does that suggest it should also depend on remodeling for function? 11. Minor comments on presentation: a. Fig. 1A , RpoS and YciR are not mentioned in the figure legend nor text; how critical are they here? Either describe briefly or remove to simplify this figure. b. Fig. 2A , either label in the figure or describe in the legend the position of pairing region in ydaM relative to the initiation codon (AUG) and how long the 5' UTR is. c. Fig. 2B , briefly describe the DNA fragment of ydaM used for generating pYdaM::GFP fusion (how much of the ORF is present, in addition to the 5' UTR). d. Fig. 3A : describe the ydaM leader length, spell out where the RT primer primes. e. Fig. 4A , B: OmrA/B binding region should be highlighted by a red, not a yellow box (according to the legend), and lane numbers should be added, would simplify discussing the results. f. Please also highlight the enhanced cuts in Fig. 4A , since these are an important part of the story (box of another color, or even green like Hfq protection ones). In Fig. 4B , note where the ydaM M2 mutation is, and please include numbering for the "open structure" as well. It would also be useful to box critical parts of Fig S4A as well. g. Page 4, the order of names in the reference should be rearranged (Geissmann & Touati 2004); h. Page 5, fix the last sentence ending with "and"; i. Page 6, "we introduced chromosomal point mutations that disrupt base-pairing with both the csgD and ompR mRNAs" this sentence is confusing, reads like mutation in OmrA/B. Consider rephrasing. j. Page 6, spell out how many "mRNAs from biofilm-associated genes" were examined, and how the list was assembled. k. Page 8 top, the pairing region is shown as starting at codon 6 (counting the AUG); is this still considered within the '5 codon window'? If not, is this worth commenting on? l. Page 8 top, for clarity, write "30S ribosomal subunit" m. Page 11, when describing results in Fig. S6 , the statement "no ydaM-OmrA complex was formed" is not accurate. A complex is obvious on the gel, although the amount is less than that in WT. Consider rephrasing. n. Page 17, E. coli (italic) o. Page 17 bottom, delete one "ug" in front of Congo red p. Referee #3 additional comments during referee cross-commenting session:
I also agree that a role for Hfq in remodeling the mRNA does not preclude it also playing a role as a "matchmaker" platform model. The in vitro data for Hfq mutants (Fig. 6A) Referee #1:
This paper reports a biochemical/mutational study on the mechanism by which OmrA/B, Hfqdependent sRNAs, inhibit the synthesis of YdaM, an upstream regulator in biofilm pathway in Escherichia coli. Major results/findings are: 1) OmrA/B inhibit the YdaM expression through basepairing with ydaM mRNA in an Hfq-dependent manner; 2) OmrA/B along with Hfq inhibit the ydaM translation in vitro; 3) OmrA/B bind two sites near the ribosome binding site of ydaM mRNA while Hfq binds to a region containing (AAN)n motifs located about 50 bp upstream of OmrA/B binding sites; 4) Hfq variant carrying a mutation in the distal face but not in the proximal face or the rim loses the ability to support the inhibition of ydaM translation in vitro by OmrA/B; 5) OmrA/B are able to inhibit the ydaM translation without Hfq in vitro when a DNA oligo complementary to the Hfq binding site of the ydaM mRNA is annealed; 6) not only the hfq distal mutation but also the hfq proximal and rim mutations fail to support the OmrA/B action on the ydaM mRNA in vivo.
Based on these results, the authors conclude that Hfq acts primarily by remodeling the structure of the target mRNA to provide access to the sRNAs to support the translational inhibition of ydaM by OmrA/B. They claim that this mechanism of Hfq action is new because Hfq is believed to act as a platform for the sRNA-mRNA pairing by binding simultaneously to two RNAs in a canonical model.
The data is overall clear and consistent with the view that Hfq supports the OmrA/B action by binding to the ydaM mRNA through the distal face resulting in the structural rearrangement. However, I hesitate to agree with the authors' claim that this work has uncovered a different and new mechanism of Hfq action. I have two major criticisms on this work/manuscript. 1) The major role of Hfq is certainly to support the sRNA action by stimulating the sRNA-mRNA base pairing. The mechanism by which Hfq stimulates the base pairing between two RNAs is not completely uncovered yet though several models, not mutually exclusive, have been proposed. The structural rearrangement of mRNA and/or sRNA by Hfq is a well-known model among them. Therefore, the authors' model is not new and not different from the conventional model. The contribution of the present work may be to have shown clearly that the structural rearrangement of a target mRNA upon Hfq binding through the distal face is critical for Hfq action. Referee #2:
We completely agree with the reviewer that the major role of Hfq lies in being a platform for sRNAs and mRNAs, which works through increased binding-rates or, possibly in some cases, ∆G effects (stabilizing of sRNA-mRNA complexes). As for the function as a remodeler: indeed, Hfq does remodel mRNAs and sRNAs, and we acknowledged this and cited such studies (Intro and Discussion
1. The authors could further test their model in vivo with select point mutations that disrupt the inhibitory secondary structure. 2. The authors should acknowledge the alternative/"official" name for ydaM is dgcM.
We discussed this among the authors and agreed that it is better to use DgcM instead (similar comment from reviewer 3). We have changed YdaM to DgcM throughout the paper.
Specific comments: 1. Given that this paper suggests that multiple levels of biofilm formation are regulated by OmrA/B, it would be helpful to have a little more information on the contribution of each of the known targets, even if it isn't the focus of this paper. While this is not essential it would be a useful addition.
We agree. We have now added significantly more information on this (see below, response to point 11), mainly on pages 5+6 in the manuscript.
a. Fig. 1B is a nice demonstration that OmrA/B do something novel for curli formation. Can the repression of curli by disrupting either target or both targets tested in Fig. 1B be quantitated (by measurement of CsgD levels, possibly), in addition to the indicator plates in Fig. 1B and Fig. S1 ?
Unfortunately, this would be a very difficult experiments for us. Ideally, we would have to move a csgB:gfp fusion by P1 transduction into a strain carrying the csgD mutation, which could be used to provide an indirect measurement of CsgD protein levels. However, the csgD mutation is markerless, and as csgB neighbors csgD on the chromosome, the mutation would likely revert back to wt in the process, which makes this a tricky endeavor. We did use antibodies against curli components before, but for whatever reason, they don't work well for us. All in all, this experiment would certainly be instructive, but we feel it might take too much time and effort.
b. Does abolishing regulation of ydaM either alone or in the double mutant used in Fig. 1B now prevent OmrA/B repression of biofilm? Fig. 1C) 
We indeed have an experiment that addresses the question asked (which we did not include in the submission). This is now described in the Results section, and the results are presented in supplementary Figure S4 (all S-figures have correspondingly been renumbered in the manuscript). This experiment, in which we circumvented the regulation of dgcM by introducing a plasmid with dgcM_M2 (from

The reviewer is correct in that we do detect some protections from G32-39 (Fig 4). Compared to, e.g., the exposed G54, cleavage (minus Hfq) is weak to begin with, and Hfq even weakens these signals. The stem region contains some weak AU, GU base-pairs and a centrally located bulged-out G, next to a weak GU, on the opposite side, which likely renders the stem less stable. This would account for some cleavage upon breathing. So, yes, we think that the stem is formed, and that Hfq causes a small effect on its structural stability nearby. Second question: We do not know whether this structure element is needed for regulation.
4. Fig. 4 : The authors interpret the protection of the lower cyan box region due to structural rearrangements; can they rule out another Hfq binding site for the protection? Clarify whether the structures in Fig. 4B are based on both mFold prediction and experimental data or only the experimental data.
For the structures shown in Fig. 4B , we used mFOLD predictions constrained by experimental data.
As for another Hfq binding site, we cannot be sure, but the region asked for by the reviewer is at least not a good candidate for direct binding, since it is far off with respect to the expected AUrichness and/or presence of ARN motifs.
5. P. 9, top, Fig. 4 : Only if the flanking sequence, apparently not protected, is included are there two (AAN)3 motifs. Is it accurate to say the outside sites are not protected (they don't appear to be in Fig. 4) ? The enhanced cleavage in the middle is noted but not really discussed. Do the authors think there are interactions between the two sub-motifs that are affecting the rearrangement and binding? Figure S5B (earlier S4B).
7. Fig. 7 : The data on a critical role of the distal face of Hfq would probably support both the usual model in which Hfq acts as a platform to bring together sRNA and mRNA and the remodeling model presented here. Or is this data only compelling in combination with Fig. S6 9. Given that all of the results here are under OmrA/B overproduction conditions, is there evidence for the endogenous levels of OmrA/B in regulation of curli and the ydaM target?
According to our unpublished data, deletion of omrA, omrB, or both all leads to an increase in curli gene expression as measured by a chromosomal csgB-yfp fusion. We are currently investigating the contribution of each OmrA/B target to the endogenous regulation in the context of motility-sessility counter-regulation and phenotypic heterogeneity. As this is part of an ongoing project we would prefer to not include these data in the current manuscript. Also, we have previously published experiments on curli regulation and effects on CsgD without sRNA overexpression (Holmqvist et al EMBO J, 2010)
10. The model here, for Hfq remodeling allowing interaction of sRNAs, was suggested initially for RyhB by Geissmann and Touati, as the authors discuss. While that case may or may not still be accurate, the authors may want to consider how widespread this mode of regulation might be. Is it likely dependent on particular types of Hfq binding sites in the target? RprA has also been found to repress ydaM (as well as csgD), and the pairing region appeared, in a quick reading (Mika et al, 2012), to overlap the OmrA/B sites. Does that suggest it should also depend on remodeling for function?
The reviewer addresses an important point. 11. Minor comments on presentation: a. Fig. 1A , RpoS and YciR are not mentioned in the figure legend nor text; how critical are they here? Either describe briefly or remove to simplify this figure. Figure. This is found on pages 5+6 in the manuscript, and a shorter addition in Discussion on p 14. We also added an additional reference to a relevant review by Hengge.
Thank you for pointing this out. We have now significantly expanded the text to explain more about the relevant transcriptional regulation of curli, and to refer to the players shown in the
b. Fig. 2A , either label in the figure or describe in the legend the position of pairing region in ydaM relative to the initiation codon (AUG) and how long the 5' UTR is. Figure legend (74 nt to AUG) , and labeled the sequence number in Fig 2B. c. Fig. 2B , briefly describe the DNA fragment of ydaM used for generating pYdaM::GFP fusion (how much of the ORF is present, in addition to the 5' UTR).
We now added this information in the
The first 641nt of the dgcM transcript, with 74nt of the UTR and 567nt of the ORF (counting from the AUG) were translationally fused to GFP. Now written in Materials and Methods.
d. Fig. 3A : describe the ydaM leader length, spell out where the RT primer primes.
The primer was (Table S1) We apologize for the mistake. Corrected.
h. Page 5, fix the last sentence ending with "and"; Done i. Page 6, "we introduced chromosomal point mutations that disrupt base-pairing with both the csgD and ompR mRNAs" this sentence is confusing, reads like mutation in OmrA/B. Consider rephrasing.
We agree. Now rephrased j. Page 6, spell out how many "mRNAs from biofilm-associated genes" were examined, and how the list was assembled.
In l. Page 8 top, for clarity, write "30S ribosomal subunit"
Done.
Page 11, when describing results in Fig. S6 , the statement "no ydaM-OmrA complex was formed" is not accurate. A complex is obvious on the gel, although the amount is less than that in WT. Consider rephrasing.
Rephrased, on page 11. Sorry, we mislabeled. This is dgcM-M2, as in Figure 2 . We changed this in Figure S2B .
Referee #3 additional comments during referee cross-commenting session:
I also agree that a role for Hfq in remodeling the mRNA does not preclude it also playing a role as a "matchmaker" platform model. The in vitro data for Hfq mutants (Fig. 6A) Thank you for submitting a revised version of your manuscript. The manuscript has now been seen by all referees, who find that their main concerns have been addressed and now recommend publication of the article. There remain only a few mainly editorial issues that have to be resolved before formal acceptance of the manuscript.
1. To address the remaining comment by referee #1, please add a brief discussion on the limitations of the in vivo support for the proposed model of Hfq action.
Referee #1:
The authors' central claim is that Hfq promotes regulation by unfolding mRNA rather than acting as a platform. Previously, I raised two major criticisms on this argument. The first is that the structural rearrangement model itself is not new. The second is that the structural rearrangement model does not exclude the platform model in vivo. While the authors have essentially agreed with my comments as described in the point-by point response, the manuscript has not been revised in a satisfactory manner. I certainly appreciate that this work has shown experimentally that unfolding mRNA target by Hfq is critical for sRNA regulation. However, the important is that this was shown only in vitro. It is possible that the simultaneous binding of Hfq to sRNA and mRNA is also critical for sRNA regulation in vivo. I understand that it is difficult to make this point clear in vivo at this stage. In addition, it is not sure whether the remodeling is prerequisite for sRNA regulation in vivo. I am afraid that the authors argue too strongly to justify their view. I think that their argument should be tone-downed because there is no evidence that Hfq acts as proposed also in vivo.
In my view, the authors have thoughtfully address all of the reviewers' comments.
The revised manuscript addresses the major questions I had, and is appropriate for EMBO J. as currently written. Any descriptions too long for the figure legend should be included in the methods section and/or with the source data.
In the pink boxes below, please ensure that the answers to the following questions are reported in the manuscript itself. Every question should be answered. If the question is not relevant to your research, please write NA (non applicable). We encourage you to include a specific subsection in the methods section for statistics, reagents, animal models and human subjects.
definitions of statistical methods and measures: a description of the sample collection allowing the reader to understand whether the samples represent technical or biological replicates (including how many animals, litters, cultures, etc.).
Please fill out these boxes # (Do not worry if you cannot see all your text once you press return) a specification of the experimental system investigated (eg cell line, species name).
C--Reagents
B--Statistics and general methods
the assay(s) and method(s) used to carry out the reported observations and measurements an explicit mention of the biological and chemical entity(ies) that are being measured. an explicit mention of the biological and chemical entity(ies) that are altered/varied/perturbed in a controlled manner.
Data
the data were obtained and processed according to the field's best practice and are presented to reflect the results of the experiments in an accurate and unbiased manner. figure panels include only data points, measurements or observations that can be compared to each other in a scientifically meaningful way. graphs include clearly labeled error bars for independent experiments and sample sizes. Unless justified, error bars should not be shown for technical replicates. if n< 5, the individual data points from each experiment should be plotted and any statistical test employed should be justified the exact sample size (n) for each experimental group/condition, given as a number, not a range;
Each figure caption should contain the following information, for each panel where they are relevant:
Captions
The data shown in figures should satisfy the following conditions:
Source Data should be included to report the data underlying graphs. Please follow the guidelines set out in the author ship guidelines on Data Presentation. 
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